STATE OF TEXAS COUNTY OF TRAVISCancer Research Grant Contract • March 29th, 2024 • Molecular Templates, Inc. • Pharmaceutical preparations • Texas
This CANCER RESEARCH GRANT CONTRACT (“Contract”) is by and between the Cancer Prevention and Research Institute of Texas (“CPRIT”), hereinafter referred to as the “INSTITUTE”, acting through its Chief Executive Officer, and Molecular Templates, Inc., hereinafter referred to as the “RECIPIENT”, acting through its authorized signing official.
CANCER PREVENTION & RESEARCH INSTITUTE OF TEXASCancer Research Grant Contract • August 24th, 2015 • Mirna Therapeutics, Inc. • Pharmaceutical preparations • Texas
This CANCER RESEARCH GRANT CONTRACT (“Contract”) is by and between the Cancer Prevention and Research Institute of Texas (“CPRIT”), hereinafter referred to as the “INSTITUTE”, acting through its Executive Director, and Mirna Therapeutics, Inc., hereinafter referred to as the “RECIPIENT”, acting through its authorized signing official.
STATE OF TEXAS COUNTY OF TRAVISCancer Research Grant Contract • February 13th, 2019 • Molecular Templates, Inc. • Pharmaceutical preparations • Texas
This CANCER RESEARCH GRANT CONTRACT (“Contract”) is by and between the Cancer Prevention and Research Institute of Texas (“CPRIT”), hereinafter referred to as the “INSTITUTE”, acting through its Chief Executive Officer, and Molecular Templates, Inc., hereinafter referred to as the “RECIPIENT”, acting through its authorized signing official.
Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the...Cancer Research Grant Contract • May 3rd, 2017 • Heat Biologics, Inc. • Pharmaceutical preparations • Texas
This CANCER RESEARCH GRANT CONTRACT (“Contract”) is by and between the Cancer Prevention and Research Institute of Texas (“CPRIT”), hereinafter referred to as the “INSTITUTE”, acting through its Chief Executive Officer, and Pelican Therapeutics, hereinafter referred to as the “RECIPIENT”, acting through its authorized signing official.
Paul Lammers, M.D., M.Sc. President and Chief Executive Officer Mirna Therapeutics, Inc.Cancer Research Grant Contract • June 21st, 2017 • Mirna Therapeutics, Inc. • Pharmaceutical preparations
RECITALSCancer Research Grant Contract • September 11th, 2015 • Mirna Therapeutics, Inc. • Pharmaceutical preparations • Texas
performed or services delivered and comply with all federal and state laws regarding the conduct of the research or service.
DP160057 Annemarie MoseleyCancer Research Grant Contract • May 5th, 2020 • Texas
STATE OF TEXAS COUNTY OF TRAVIS This CANCER RESEARCH GRANT CONTRACT (“Contract”) is by and between the Cancer Prevention and Research Institute of Texas (“CPRIT”), hereinafter referred to as the “INSTITUTE”, acting through its Chief Executive Officer, and Bellicum Pharmaceuticals, Inc., hereinafter referred to as the “RECIPIENT”, acting through its authorized signing official. RECITALS WHEREAS, pursuant to TEX. HEALTH & SAFETY CODE, Ch. 102, the INSTITUTE may make grants to public and private persons in this state for research into the causes and cures for all types of cancer in humans; facilities for use in research into the causes and cures for cancer; research to develop therapies, protocols, medical pharmaceuticals, or procedures for the cure or substantial mitigation of all types of cancer; and cancer prevention and control programs. WHEREAS, Article III, Section 67 of the Texas Constitution expressly authorizes the State of Texas to sell general obligation bonds on behalf of the
Grant ID: DP140067 Attachment F - Contract AmendmentCancer Research Grant Contract • June 21st, 2017 • Mirna Therapeutics, Inc. • Pharmaceutical preparations
Contract Document F: This Attachment (this “Attachment”), dated as of May 11, 2017, is hereby incorporated into and made a part of that certain CANCER RESEARCH GRANT CONTRACT (“Contract”) effective as of June 1, 2014 by and between the Cancer Prevention and Research Institute of Texas (“CPRIT” or the “INSTITUTE”) and Mirna Therapeutics, Inc. (the “RECIPIENT”). A capitalized term used in this Attachment shall have the meaning given the term in the Contract or in the Attachments to the Contract, unless otherwise defined herein. In the event of a conflict between the provisions of this Attachment and the provisions of the Contract, this Attachment shall control. 1. Mirna hereby provides notice of its intent to terminate that certain Cancer Research Grant Contract by and between CPRIT and Mirna effective as of June 1, 2014 (including any attachments thereto, the (“2014 Contract”) pursuant to Section 8.04 thereof. The termination of the 2014 Contract will be made prior to the Termination Da
RECITALSCancer Research Grant Contract • June 16th, 2015 • Aeglea BioTherapeutics, Inc. • Pharmaceutical preparations • Texas
Section C1.04 Conduct of Research or Service Provided. RECIPIENT understands that the Project must be conducted with full consideration for the ethical and medical implications of the research performed or services delivered and comply with all federal and state laws regarding the conduct of the research or service.
STATE OF TEXAS COUNTY OF TRAVISCancer Research Grant Contract • November 18th, 2014 • Bellicum Pharmaceuticals, Inc • Pharmaceutical preparations • Texas
This CANCER RESEARCH GRANT CONTRACT (“Contract”) is by and between the Cancer Prevention and Research Institute of Texas (“CPRIT”), hereinafter referred to as the “INSTITUTE”, acting through its Executive Director, and Bellicum Pharmaceuticals, Inc., hereinafter referred to as the “RECIPIENT”, acting through its authorized signing official.
Confidential Treatment Requested. Confidential portions of this document have been redacted and have been separately filed with the Commission.Cancer Research Grant Contract • February 14th, 2019 • Flex Pharma, Inc. • Pharmaceutical preparations • Texas
This CANCER RESEARCH GRANT CONTRACT (“Contract”) is by and between the Cancer Prevention and Research Institute of Texas (“CPRIT”), hereinafter referred to as the “INSTITUTE”, acting through its Chief Executive Officer, and Salarius Pharmaceuticals LLC, hereinafter referred to as the “RECIPIENT”, acting through its authorized signing official.
Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 406 of the Securities Exchange Act of 1933, as amended. A complete copy of this document has been filed separately with the Securities...Cancer Research Grant Contract • August 24th, 2018 • Versartis, Inc. • Pharmaceutical preparations • Texas
This CANCER RESEARCH GRANT CONTRACT (“Contract”) is by and between the Cancer Prevention and Research Institute of Texas (“CPRIT”), hereinafter referred to as the “INSTITUTE”, acting through its Chief Executive Officer, and Ruga Corporation, hereinafter referred to as the “RECIPIENT”, acting through its authorized signing official.
Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 406 of the Securities Exchange Act of 1933, as amended. A complete copy of this document has been filed separately with the Securities...Cancer Research Grant Contract • August 3rd, 2018 • Versartis, Inc. • Pharmaceutical preparations • Texas
This CANCER RESEARCH GRANT CONTRACT (“Contract”) is by and between the Cancer Prevention and Research Institute of Texas (“CPRIT”), hereinafter referred to as the “INSTITUTE”, acting through its Chief Executive Officer, and Ruga Corporation, hereinafter referred to as the “RECIPIENT”, acting through its authorized signing official.
